infect
copd
airway
colon
chronic
infect
new
strain
exacerb
pneumonia
copd
innat
immun
copd
virul
factor
viciouscircl
hypothesi
infect
chronic
obstruct
pulmonari
diseas
copd
regard
comorbid
condit
infect
contribut
progress
copd
copd
alter
suscept
manifest
lung
infect
underli
mechan
acut
exacerb
copd
acquisit
new
strain
bacteria
virus
complex
hostpathogen
interact
determin
clinic
manifest
outcom
acquisit
copd
predispos
communityacquir
pneumonia
alter
caus
treatment
outcom
sever
line
evid
suggest
chronic
airway
infect
bacteria
preval
copd
trigger
chronic
inflammatori
respons
contribut
progress
diseas
lung
innat
immun
defens
impair
copd
make
patient
suscept
infect
respiratori
pathogen
preval
copd
use
variou
mechan
evad
host
respons
therebi
caus
acut
persist
infect
role
infect
chronic
obstruct
pulmonari
diseas
copd
first
postul
stuartharri
colleagu
known
british
hypothesi
specul
declin
lung
function
copd
result
mucu
hypersecret
recurr
bacteri
infect
next
decad
sever
studi
perform
confirm
hypothesi
studi
sputum
microbiolog
use
compar
rate
bacteri
infect
patient
chronic
bronchiti
baselin
exacerb
well
comparison
individu
without
copd
differ
bacteri
infect
relat
diseas
state
found
exampl
smith
colleagu
haemophilu
influenza
patient
sever
copd
compar
mild
copd
howev
part
differ
rate
bacteri
isol
sputum
stabl
state
ie
colon
versu
acut
exacerb
ie
infect
seen
studi
advanc
molecular
biolog
techniqu
differenti
bacteri
strain
within
speci
develop
therefor
avail
investig
investig
examin
hypothesi
use
serolog
studi
determin
level
antibacteri
antibodi
patient
chronic
bronchiti
result
also
confus
contradictori
confound
use
laboratori
strain
antigen
discuss
ref
fletcher
colleagu
publish
landmark
studi
show
frequenc
exacerb
mucu
hypersecret
result
faster
declin
lung
function
patient
copd
earli
observ
appreci
import
tobacco
smoke
copd
pathogenesi
british
hypothesi
reject
bacteri
infect
releg
epiphenomenon
diseas
role
viral
infect
copd
exacerb
also
extens
investig
viral
cultur
serolog
exacerb
lack
confound
chronic
colon
serolog
cross
reactiv
exacerb
confirm
viral
origin
follow
year
scant
investig
role
infect
revisit
last
decad
new
molecular
biolog
immunolog
microbiolog
techniqu
understand
infect
copd
acut
chronic
set
consequ
develop
substanti
discuss
later
fig
acut
infect
copd
clinic
recogn
either
exacerb
episod
pneumonia
differenti
two
present
base
presenc
pneumonia
absenc
exacerb
lung
parenchym
involv
present
infiltr
chest
radiolog
although
pneumonia
alway
consid
signific
acut
infect
exacerb
occur
much
greater
frequenc
also
seriou
consequ
copd
british
hypothesi
larg
discredit
import
exacerb
copd
also
minim
came
regard
selfresolv
viral
ill
littl
consequ
chest
cold
specif
therapi
avail
part
natur
cours
diseas
last
decad
seen
consider
revis
point
view
data
emerg
exacerb
contribut
loss
qualiti
life
lung
function
copd
account
much
half
cost
care
copd
furthermor
bacteri
infect
contribut
exacerb
specif
therapi
benefit
prevent
exacerb
possibl
import
therapeut
goal
copd
exacerb
copd
airway
inflammatori
event
induc
infect
instanc
aggrav
infect
viral
bacteri
combin
viral
bacteri
infect
although
episod
induc
poorli
understood
noninfecti
factor
infect
like
account
exacerb
tabl
role
virus
exacerb
establish
older
studi
discuss
earlier
viral
cultur
serolog
understand
viral
exacerb
recent
expand
use
molecular
diagnost
techniqu
develop
human
experiment
model
rhinovir
exacerb
common
virus
detect
airway
secret
exacerb
rhinoviru
influenza
respiratori
syncyti
viru
rsv
parainfluenza
adenoviru
recent
systemat
review
found
virus
detect
exacerb
recent
studi
use
molecular
detect
viru
polymeras
chain
reaction
pcr
techniqu
found
virus
half
exacerb
human
experiment
model
rhinovir
exacerb
describ
studi
subject
copd
control
subject
nasal
inocul
low
dose
rhinoviru
increas
neutrophil
inflammatori
respons
lower
airway
promin
lower
respiratori
symptom
airway
obstruct
found
copd
compar
control
impair
interferon
respons
infect
seen
patient
copd
work
confirm
viral
causat
exacerb
provid
insight
suscept
pathogen
mechan
involv
viral
exacerb
contrast
role
virus
role
bacteria
caus
exacerb
controversi
fulli
appreci
recent
present
pathogen
clearli
implic
copd
exacerb
nontyp
h
influenza
streptococcu
pneumonia
moraxella
catarrhali
pseudomona
aeruginosa
whether
staphylococcu
aureu
gramneg
enter
bacteria
enterobacteriacea
frequent
isol
sputum
copd
caus
exacerb
capabl
airway
colon
unclear
present
previou
studi
defin
bacteri
pathogen
isol
sputum
speci
level
unabl
fulli
appreci
dynam
natur
bacteri
infect
copd
longitudin
prospect
cohort
studi
patient
copd
bacteri
strain
sputum
character
molecular
techniqu
combin
care
analysi
host
immun
immunolog
respons
import
mechan
like
underli
exacerb
caus
major
pathogen
list
earlier
found
fig
risk
exacerb
increas
respiratori
tract
acquisit
strain
bacteri
pathogen
new
patient
initi
studi
visit
within
month
new
strain
acquisit
associ
exacerb
compar
without
new
strain
subsequ
analys
studi
shown
incid
exacerb
visit
new
strain
isol
sputum
hold
true
major
pathogen
nontyp
h
influenza
pneumonia
catarrhali
p
aeruginosa
addit
support
mechan
exacerb
come
variou
observ
exacerbationassoci
strain
h
influenza
inflammatori
vitro
anim
model
strain
associ
colon
show
clinic
implic
bacteri
acquisit
correl
strain
virul
strainspecif
host
immun
respons
vigor
neutrophil
inflammatori
respons
distinguish
new
strain
exacerb
without
new
strain
whether
increas
bacteri
concentr
load
airway
preexist
colon
strain
addit
independ
mechan
exacerb
controversi
bacteri
sputum
concentr
longitudin
cohort
studi
analyz
either
differ
small
differ
found
stabl
diseas
exacerb
small
differ
longer
seen
new
strain
acquisit
taken
account
contrast
rosel
colleagu
show
pool
analysi
data
bronchoscop
protect
brush
specimen
patient
copd
exacerb
pathogen
bacteria
present
airway
secret
signific
concentr
compar
patient
stabl
copd
intracellular
h
influenza
found
bronchial
mucos
biopsi
intub
patient
copd
exacerb
compar
patient
stabl
copd
garcha
colleagu
use
quantit
pcr
found
higher
sputum
bacteri
load
exacerb
stabl
state
howev
studi
shown
higher
bacteri
load
sputum
exacerb
taken
account
bacteri
strain
variat
specimen
recent
studi
examin
impact
simultan
sequenti
bacteri
viral
infect
exacerb
papi
colleagu
examin
patient
copd
exacerb
requir
hospit
admiss
combin
bacteri
viral
infect
patient
sever
symptom
longer
hospit
presenc
cold
symptom
h
influenza
sputum
also
associ
symptom
larger
decreas
lung
function
either
present
alon
rhinovir
human
experiment
model
discuss
earlier
mani
patient
copd
develop
secondari
bacteri
infect
greater
inflammatori
respons
durat
symptom
howev
sever
exacerb
mild
none
patient
requir
steroid
antibiot
like
viral
infect
predispos
suscept
host
bacteri
coinfect
vice
versa
cultur
airway
epitheli
cell
sajjan
colleagu
found
infect
h
influenza
increas
express
intercellular
adhes
molecul
icam
tolllik
receptor
tlr
receptor
rhinoviru
doublestrand
rna
contrast
anoth
experiment
model
avadhanula
colleagu
found
increas
bacteri
adhes
respiratori
epitheli
cell
viral
infect
human
rhinoviru
experiment
model
degrad
antimicrobi
peptid
elafin
neutrophil
elastas
could
explain
occurr
secondari
bacteri
infect
summari
bacteri
viral
infect
play
critic
role
copd
exacerb
applic
molecular
diagnost
techniqu
exacerb
like
enhanc
understand
infecti
episod
role
opportunist
bacteri
pathogen
caus
exacerb
still
need
defin
epidemiolog
communityacquir
pneumonia
cap
major
caus
morbid
mortal
worldwid
incid
per
adult
mortal
reach
mortal
risk
attribut
smoke
second
age
multivari
analysi
copd
independ
risk
factor
develop
sever
cap
odd
ratio
evalu
copd
subgroup
reveal
sever
copd
home
oxygen
sever
copd
exacerb
requir
hospit
independ
risk
factor
develop
cap
merinosanchez
colleagu
observ
incid
pneumonia
patient
copd
year
case
pneumonia
sever
index
psi
mortal
psi
european
studi
hospit
patient
cap
without
copd
compar
although
mortal
differ
group
seen
patient
copd
experienc
sever
pneumonia
higher
rate
readmiss
recurr
pneumonia
lower
serum
tumor
necrosi
factor
alpha
tnfa
level
seen
copd
group
suggest
impair
inflammatori
respons
patient
higher
mortal
cap
copd
observ
studi
reiter
import
earli
recognit
appropri
manag
highrisk
popul
caus
cap
copd
pneumonia
remain
common
caus
cap
copd
howev
alter
lung
microbiom
copd
pathogen
h
influenza
catarrhali
p
aeruginosa
may
play
larger
role
develop
cap
patient
moreov
patient
copd
expos
frequent
antibiot
cours
like
infect
antibioticresist
pathogen
make
empir
antibiot
choic
challeng
studi
hospit
patient
copd
cap
infect
attribut
p
aeruginosa
observ
howev
use
respiratori
specimen
determin
microbiolog
caus
cap
copd
challeng
chronic
colon
capassoci
pathogen
common
copd
inhal
corticosteroid
ic
combin
long
act
beta
agonist
laba
wide
use
copd
reduc
frequenc
exacerb
daili
symptom
patient
howev
benefit
come
cost
increas
risk
pneumonia
increas
risk
origin
observ
torch
toward
revolut
copd
health
studi
icslaba
group
higher
probabl
develop
pneumonia
cours
year
recent
metaanalysi
random
control
trial
ic
copd
confirm
result
calcul
rel
risk
develop
pneumonia
number
need
harm
howev
mortal
differ
use
laba
alon
associ
ic
use
pneumonia
interpret
caution
none
trial
specif
design
assess
risk
pneumonia
episod
lack
radiolog
confirm
copd
exacerb
may
misdiagnos
pneumonia
mechan
underli
associ
examin
corticosteroidinduc
impair
local
immun
respons
microbi
pathogen
like
respons
outpati
cap
presenc
copd
comorbid
condit
place
highrisk
group
treatment
respiratori
fluoroquinolon
blactam
plu
macrolid
recommend
monotherapi
macrolid
doxycyclin
appropri
patient
antibiot
use
common
patient
review
antibiot
use
previou
month
guid
empir
choic
antibiot
class
use
previou
month
avoid
among
inpati
cap
copd
choic
applic
howev
patient
requir
intens
care
admiss
combin
therapi
alway
recommend
blactam
respiratori
fluoroquinolon
macrolid
pseudomona
suspect
previou
pseudomona
isol
bronchiectasi
malnutrit
recent
broadspectrum
antibiot
exposur
antipseudomon
regimen
recommend
contrast
almost
steril
airway
healthi
lung
lower
airway
patient
copd
frequent
colon
bacteria
although
wide
varieti
pathogen
isol
two
common
h
influenza
p
aeruginosa
see
tabl
recent
presenc
bacteria
regard
colon
impli
innocu
process
airway
without
sequela
grow
bodi
evid
suggest
colon
stabl
copd
via
complex
interact
host
immuneinflammatori
system
could
contribut
copd
pathogenesi
progress
similar
bronchiectasi
cystic
fibrosi
hostpathogen
interact
stabl
copd
well
describ
viciouscircl
hypothesi
fig
repeat
insult
lung
smoke
environment
exposur
lead
impair
host
immun
defens
thu
allow
bacteri
colon
bacteria
caus
subclin
inflammatori
respons
airway
result
damag
innat
lung
defens
persist
chronic
bacteri
infect
process
acceler
acut
exacerb
colon
defin
absenc
damag
effect
host
relat
presenc
pathogen
absenc
specif
immun
respons
sever
part
bodi
colon
seen
eg
skin
colon
essenti
health
microbi
pathogen
colon
surfac
constitut
microbiom
recent
advanc
research
technolog
especi
highthroughput
genom
character
made
possibl
character
microbiom
healthi
lung
steril
standard
cultur
techniqu
even
molecular
techniqu
microbiom
healthi
lung
spars
transient
compos
primarili
oral
flora
microaspir
clear
contrast
third
patient
copd
potenti
respiratori
pathogen
retriev
cultur
lower
airway
sampl
abund
microbiom
found
molecular
techniqu
copd
lung
unlik
bodi
surfac
like
skin
gut
mucosa
lung
well
equip
handl
microbiom
therefor
microbi
presenc
lower
airway
copd
harm
sever
studi
describ
excess
inflamm
stabl
patient
copd
colon
bacteri
pathogen
airway
inflamm
associ
bacteri
colon
predominantli
neutrophil
studi
compar
sputum
sampl
colon
noncolon
patient
found
higher
level
tnfa
leukotrien
neutrophil
myeloperoxidas
elastas
lower
level
antiproteas
secretori
leukocyt
proteas
inhibitor
bronchoscop
sampl
lower
airway
bronchoalveolar
lavag
show
increas
level
neutrophil
tnfa
matrix
metalloproteinas
endotoxin
associ
bacteri
colon
although
sever
mediat
contribut
copd
pathogenesi
particular
associ
increas
exacerb
frequenc
longer
recoveri
period
worsen
airway
obstruct
develop
bronchiectasi
bacteri
catarrhali
acquisit
even
without
increas
symptom
exacerb
associ
increas
proteolyt
activ
reduct
antiproteolyt
defens
result
worsen
proteaseantiproteas
imbal
thought
caus
progress
lung
damag
copd
inflammatori
profil
seen
bacteri
colon
similar
seen
bacteri
exacerb
impli
colon
lowgrad
infect
follow
exacerb
copd
specif
immun
respons
system
mucos
infect
strain
often
observ
similar
observ
describ
follow
colon
activ
immun
respons
support
presenc
chronic
infect
copd
furthermor
catarrhali
differenti
immun
respons
seen
colon
accompani
stronger
mucos
immun
respons
compar
stronger
system
immun
respons
accompani
exacerb
whether
natur
immun
respons
dictat
clinic
express
infect
vice
versa
clear
potenti
contribut
viral
atyp
pathogen
chronic
infect
copd
controversi
latent
adenovir
infect
lung
form
integr
portion
adenovir
dna
cellular
dna
found
enhanc
inflammatori
respons
tobacco
smoke
therebi
thought
contribut
copd
pathogenesi
initi
studi
show
adenovir
integr
common
copd
control
howev
subsequ
studi
support
observ
latent
rsv
infect
describ
copd
one
group
investig
found
other
presenc
contribut
chronic
chlamydi
lung
infect
copd
remain
similarli
controversi
inconsist
observ
variou
investig
besid
direct
microbiolog
evid
infect
consequ
indirect
line
evid
chronic
infect
copd
emerg
radiolog
patholog
studi
patholog
studi
small
airway
patient
copd
extent
format
lymphoid
aggreg
predominantli
compos
b
cell
best
correl
degre
airflow
obstruct
like
aggreg
repres
local
host
immun
respons
chronic
microbi
infect
furthermor
patholog
find
replic
mous
model
chronic
inflamm
lung
induc
repeat
instil
nontyp
h
influenza
lysat
widespread
use
high
resolut
comput
tomographi
scan
reveal
bronchiectasi
develop
substanti
proport
patient
copd
comprehens
studi
patient
stabl
moder
sever
diseas
bronchiectasi
presenc
relat
wors
lung
function
hospit
admiss
past
year
chronic
bronchit
symptom
repeat
sputum
cultur
patient
link
chronic
colon
potenti
bacteri
pathogen
predominantli
nontyp
h
influenza
p
aeruginosa
presenc
bronchiectasi
summari
variou
line
investig
support
paradigm
viciou
circl
infect
inflamm
copd
howev
copd
heterogen
diseas
like
patient
chronic
infect
play
promin
role
one
chronic
colon
bronchiectasi
andor
chronic
bronchiti
futur
longitudin
natur
histori
studi
studi
intervent
decreas
bacteri
colon
measur
diseas
progress
need
prove
viciouscircl
hypothesi
although
infect
comorbid
condit
copd
much
learn
incid
consequ
infect
diseas
understand
mechan
underli
increas
suscept
infect
seen
copd
still
earli
stage
alter
host
pathogen
contribut
establish
acut
chronic
infect
play
role
copd
disrupt
host
increas
suscept
infect
categor
chang
innat
adapt
lung
defens
pathogen
alter
includ
host
defens
evas
mechan
healthi
lung
possess
multilay
redund
highli
effici
innat
defens
system
allow
maintain
almost
pathogenfre
environ
spite
constantli
expos
varieti
microb
inhal
microaspir
innat
immun
system
lung
compon
mechan
barrier
humor
cellular
respons
system
nonspecif
immun
first
line
defens
virus
bacteria
particul
recogn
antigen
ligand
enter
airway
via
patternrecognit
receptor
trigger
seri
respons
result
complement
activ
phagocytosi
end
result
elimin
antigen
present
surfac
macrophag
activ
adapt
immun
patient
copd
sever
innat
respons
impair
lead
increas
suscept
infect
mucociliari
clearanc
first
barrier
noxiou
agent
effect
trap
clear
inhal
microaspir
microbi
pathogen
normal
mucu
normal
ciliari
apparatu
requir
effect
mucociliari
clearanc
abnorm
mucu
cystic
fibrosi
dysfunct
ciliari
apparatu
ciliari
dyskinesia
associ
acut
chronic
bronchial
infect
augment
mucu
product
regard
defens
respons
particul
microbi
exposur
howev
exposur
chronic
inflamm
ciliari
dysfunct
also
present
could
worsen
mucociliari
clearanc
smoke
disrupt
mucociliari
clearanc
augment
mucu
product
also
induc
structur
abnorm
ciliari
apparatu
studi
moder
heavi
smoker
shown
longer
lung
clearanc
time
although
degre
impair
variabl
deterior
mucociliari
clearanc
seen
develop
chronic
bronchiti
airway
obstruct
smoker
patient
copd
hypertrophi
hyperplasia
airway
goblet
cell
increas
mucu
store
tissu
anim
model
exposur
pneumonia
h
influenza
result
upregul
mucin
product
neutrophil
inflamm
also
worsen
mucociliari
function
mediat
increas
mucu
product
reduc
ciliari
beat
alter
viscoelast
properti
mucu
immunoglobulin
immunoglobulin
ig
especi
polymer
secretori
iga
play
import
role
innat
defens
coat
bacteri
pathogen
therebi
interf
abil
interact
mucos
surfac
immun
exclus
iga
also
neutral
infecti
agent
could
act
opsonin
assist
pathogen
elimin
local
area
iga
defici
larg
small
airway
seen
copd
associ
squamou
metaplasia
polymer
igg
receptor
express
receptor
requir
transcytosi
iga
molecul
basolater
apic
surfac
epitheli
cell
reduc
area
chang
iga
could
import
mechan
infect
suscept
copd
antimicrobi
polypeptid
abund
airway
surfac
line
fluid
antimicrobi
immunoregulatori
function
one
major
group
cation
polypeptid
includ
lysozym
lactoferrin
defensin
cathelicidin
secretori
leukocyt
proteas
inhibitor
slpi
anoth
import
group
collectin
includ
surfact
proteina
spa
surfact
proteind
spd
mannosebind
lectin
complex
dynam
alter
variou
antimicrobi
polypeptid
describ
copd
stabl
state
exacerb
defici
slpi
lysozym
stabl
state
associ
frequent
exacerb
decreas
serum
mannosebind
lectin
link
exacerb
frequenc
copd
consist
observ
lower
airway
concentr
spa
spd
seen
smoker
decreas
associ
emphysema
lower
level
betadefensin
clara
cell
protein
increas
level
elafin
slpi
sputum
supernat
stabl
copd
observ
decreas
level
betadefensin
central
airway
distal
airway
smoker
copd
found
studi
resect
lung
specimen
dynam
chang
antimicrobi
peptid
also
describ
exacerb
copd
slpi
level
decreas
significantli
time
exacerb
return
baselin
resolut
lysozym
lactoferrin
level
decreas
level
increas
colon
infect
exacerb
h
influenza
catarrhali
human
model
rhinovir
infect
impair
elafin
slpi
respons
follow
rhinovir
infect
associ
secondari
bacteri
infect
macrophag
function
key
cellular
compon
innat
lung
defens
alveolar
macrophag
airway
epitheli
cell
phagocyt
cytokin
respons
alveolar
macrophag
bacteri
pathogen
crucial
deal
small
pathogen
inocula
without
invok
potenti
damag
inflammatori
adapt
immun
respons
alveolar
macrophag
patient
copd
show
impair
abil
phagocytos
h
influenza
catarrhali
pneumonia
inert
microspher
impair
correl
worsen
lung
function
fig
alveolar
macrophag
patient
copd
also
less
robust
cytokin
respons
bacteri
protein
specif
outer
membran
protein
lipooligosaccharid
endotoxin
h
influenza
follow
exposur
rhinoviru
alveolar
macrophag
show
decreas
cytokin
respons
bacteri
lipopolysaccharid
lipoteicho
acid
could
explain
increas
suscept
bacteri
infect
viral
infect
copd
decrement
macrophag
function
like
secondari
sever
mechan
includ
reduct
patternrecognit
receptor
tolllik
receptor
reduct
scaveng
receptor
macrophag
receptor
collagen
structur
marco
alter
subpopul
macrophag
airway
found
downregul
smoker
patient
copd
farmer
expos
organ
dust
downregul
associ
develop
emphysema
wors
airflow
limit
smoker
polymorph
gene
associ
develop
copd
phenotyp
smoker
tissu
invas
h
influenza
tradit
regard
extracellular
pathogen
howev
molecular
detect
techniqu
shown
pathogen
bronchial
epithelium
insid
subepitheli
macrophag
copd
tissu
bacteria
could
shield
action
antibiot
antibodi
therefor
could
resist
erad
molecular
detect
often
detect
h
influenza
airway
secret
lung
sampl
cultur
neg
could
explain
tissu
invas
biofilm
bacteria
encas
extracellular
matrix
usual
compos
polysaccharid
produc
secret
bacteria
bacteria
core
film
predominantli
anaerob
low
metabol
state
antibiot
penetr
biofilm
limit
requir
time
higher
concentr
achiev
erad
part
biofilm
detach
caus
distant
infect
pathogen
common
copd
includ
h
influenza
catarrhali
p
aeruginosa
capabl
biofilm
format
furthermor
smoke
exposur
shown
increas
biofilm
format
p
aeruginosa
cystic
fibrosi
prototyp
exampl
biofilm
format
mechan
persist
lung
whether
bacteri
biofilm
present
copd
airway
yet
known
mucoid
p
aeruginosa
strain
h
influenza
persist
clinic
long
period
spite
repeat
antibiot
exposur
reminisc
cystic
fibrosi
pathogen
evad
host
immun
respons
alter
surfac
protein
target
host
immun
system
outer
membran
protein
h
influenza
major
target
bactericid
antibodi
copd
show
extens
antigen
variat
among
strain
pathogen
serial
persist
isol
h
influenza
copd
show
diminut
highmolecularweight
adhesin
express
could
repres
anoth
immun
evas
mechan
role
infect
copd
evolv
topic
extens
ongo
research
tri
better
understand
hostpathogen
interact
find
suitabl
target
intervent
although
exacerb
pathogenesi
better
understood
much
still
need
learn
pathogen
virul
causal
overlap
viciouscircl
hypothesi
expos
complex
interact
smoke
innat
immun
respiratori
pathogen
augment
modul
innat
adapt
host
immun
well
formul
novel
antibacteri
agent
vaccin
paramount
futur
research
develop
copd
